News und Analysen

If you're investing in dividend stocks, you should prioritize investments that increase their payouts. That way, the recurring dividend income you receive can potentially stay ahead of inflation.

A

Investors looking to participate in the stock market have a multitude of options, and it can sometimes be hard to separate the wheat from the chaff. But some companies look especially attractive

In this podcast, Motley Fool senior analyst Bill Mann and host Deidre Woollard discuss:

Motley Fool host Ricky Mulvey and analyst Kirsten Guerra take a look at Vertex Pharmaceuticals and its role at

Over time, stocks with growing dividends and high returns on invested capital (ROICs) have tended to outperform their peers. By highlighting these qualities -- plus a payout ratio below 50% --

Despite its shares being down almost 10% over the past five years, there's reason to believe that CRISPR Therapeutics (NASDAQ: CRSP) is finally about to soar. With its first medicines approaching

The primary objective of dividend growth investing is to build an investment portfolio that can provide an investor with reliable and growing streams of passive income. The dividends can be used

An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration

On June 11, the gene sequencing giant Illumina (NASDAQ: ILMN) announced that its CEO, Francis deSouza, resigned after a tenure of roughly 10 years and that the company would start looking for a

While 2022 was disastrous for much of the market, 2023 is shaping up to be much better, with the S&P 500 already up nearly 15% so far this year. Long-term investors understand that these ups and

Shares of health insurance benefits managers dropped last Wednesday after the largest member of their industry, UnitedHealth Group (NYSE: UNH), issued a minor warning. Speaking at an investor

Biogen (NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug

For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start. The SPDR S&P Biotech Index ETF, an industry benchmark, has climbed

Buy on the dip. Most investors have heard the old saying. However, it's only good advice when a stock is likely to rebound strongly.

Three Motley Fool contributors think they've identified stocks

Soon enough, there's a big chance that the plucky biotech Coherus Biosciences (NASDAQ: CHRS) is going to be eating AbbVie's (NYSE: ABBV) lunch. Assuming it does, it's not going to be stealing a fry

You can earn monthly dividend income in a few ways:

Today, I look at three blue chip stocks that are trading at reasonable valuations and will have you receiving a dividend paycheck every month. One

When looking for bargains at a store, you might go to the sale rack. With the stock market, you might look to some of the stocks that have tumbled over the past several months. Even though the three

Shares of healthcare insurer UnitedHealth Group (NYSE: UNH) were down more than 7% Wednesday afternoon after falling as much as 9.3% earlier in the day. The drop in the stock came after comments by

Shares of several health insurers were sinking on Wednesday. Centene (NYSE: CNC) stock was down 7.9% as of 12:13 p.m. ET, while CVS Health (NYSE: CVS) and Humana (NYSE: HUM) shares were falling 6.1%

According to an old proverb, good things come to those who wait. That tends to be true in the stock market, at least for investors who buy shares of quality companies. Waiting, being patient, and

Investor enthusiasm can wax and wane -- sometimes dramatically. Consider CRISPR Therapeutics (NASDAQ: CRSP), which is trading for around $61 a share, down from its high of $220.20 on Jan. 15, 2021.

Shares of Surmodics (NASDAQ: SRDX) were up 16% early Tuesday afternoon as the healthcare company, which provides chemicals for in vitro diagnostic immunoassay tests and makes coatings for

CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug

The stock market has the potential to make just about anybody with enough patience and discipline a millionaire. This is because it has historically delivered 10% annual total returns over the long

Pharmaceutical companies Novo Nordisk (NYSE: NVO) and AbbVie (NYSE: ABBV) seem to be headed in separate directions.

Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and

Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on